NCT02202551View on ClinicalTrials.gov

Open-Label Safety Study of ADS-5102 in PD Patients With LID

PHASE3CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
DyskinesiaLevodopa Induced Dyskinesia (LID)Parkinson's Disease (PD)
Interventions
DRUG

ADS-5102

Trial Locations (87)

1080

Vienna

1220

Vienna

6020

Innsbruck

10003

New York

10016

New York

10029

New York

11725

Commack

12163

Berlin

12208

Albany

13353

Berlin

13385

Marseille

14547

Beelitz-Heilstätten

17033

Hershey

19107

Philadelphia

21075

Elkridge

21287

Baltimore

22291

Hamburg

24018

Roanoke

26506

Morgantown

27405

Greensboro

27607

Raleigh

30329

Atlanta

31059

Toulouse

32209

Jacksonville

32607

Gainesville

33076

Bordeaux

33331

Weston

33351

Sunrise

33486

Boca Raton

33612

Tampa

33613

Tampa

33980

Port Charlotte

34102

Naples

34128

Kassel

34295

Montpellier

35033

Rennes

35043

Marburg

35233

Birmingham

37075

Göttingen

43614

Toledo

44195

Cleveland

45219

Des Moines

Cincinnati

48025

Bingham Farms

48322

West Bloomfield

53233

Milwaukee

55427

Golden Valley

59037

Lille

60611

Chicago

60612

Chicago

63003

Clermont-Ferrand

63110

St Louis

66160

Kansas City

67098

Strasbourg

69677

Bron

74136

Tulsa

75390

Dallas

76031

Rouen

80045

Aurora

80804

München

81675

München

85013

Phoenix

85259

Scottsdale

85351

Sun City

86021

Poitiers

90505

Torrance

91105

Pasadena

91335

Reseda

92708

Fountain Valley

93003

Ventura

94085

Sunnyvale

95817

Sacramento

98034

Kirkland

06040

Manchester

02114

Boston

77030-1

Houston

77030-2

Houston

T6G 2B7

Edmonton

M5T 2S8

Toronto

S4T 1A5

Regina

04103

Leipzig

07751

Gera

07646

Stadtroda

08028

Barcelona

08035

Barcelona

08036

Barcelona

08041

Barcelona

Sponsors
All Listed Sponsors
lead

Adamas Pharmaceuticals, Inc.

INDUSTRY

NCT02202551 - Open-Label Safety Study of ADS-5102 in PD Patients With LID | Biotech Hunter | Biotech Hunter